Investment Rating - The report maintains a "Recommended" investment rating for the company, with a current stock price of 280.45 CNY [1]. Core Insights - The company achieved a revenue of 1.867 billion CNY in the first three quarters of 2025, representing a year-over-year increase of 22.47%. The net profit attributable to shareholders was 623 million CNY, up 18.02% year-over-year [5]. - In Q3 alone, the company generated 654 million CNY in revenue, a 24.77% increase year-over-year, with a net profit of 198 million CNY, reflecting a 6.77% growth [5]. - The company is focusing on strengthening its competitive advantage in the coronary field while expanding its market presence in peripheral areas and accelerating the domestic replacement of electrophysiology products [7]. Financial Performance - The company is projected to achieve revenues of 2.589 billion CNY in 2025, with a year-over-year growth rate of 25.3%. The net profit is expected to reach 828 million CNY, reflecting a 22.9% increase [8]. - The gross margin is expected to stabilize around 72.8% in 2025, with a net margin of 32.0% [12]. - The company’s R&D expenses are anticipated to increase significantly, contributing to a temporary pressure on net profit margins but laying a solid foundation for long-term growth [9]. Market Strategy - The company plans to enhance its international marketing team and focus on local market development in key regions such as Asia-Pacific, CIS, and Latin America [10]. - The strategy includes product penetration, academic enhancement, and channel construction in overseas markets [8]. Financial Ratios - The company’s asset-liability ratio is projected to remain low at 14.3% in 2024, indicating strong financial health [12]. - The return on equity (ROE) is expected to be 26.8% in 2024, reflecting the company's effective use of equity capital [12]. Future Projections - The report adjusts the net profit forecast for 2025-2027 to 828 million CNY, 1.070 billion CNY, and 1.377 billion CNY respectively, due to the anticipated growth from new product launches and significant domestic and international market opportunities [10].